DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Megace (Megestrol) - Death - Suspected Cause - Side Effect Reports

 
 



Index of reports > Death (5)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Megace (Megestrol) death. The selected reports were submitted to the FDA during the sample period of about a year.

Possible Megace side effects in female

Reported by a health professional (non-physician/pharmacist) from Denmark on 2012-04-19

Patient: female

Reactions: Overdose, Thrombocytopenia

Adverse event resulted in: death, life threatening event

Drug(s) suspected as cause:
Citalopram Hydrobromide
    Dosage: citalopram overdose: 60 mg daily
    Administration route: Oral
    Indication: Depression
    Start date: 2012-01-19
    End date: 2012-02-10

Megace
    Dosage: 1 df
    Administration route: Oral
    Indication: Decreased Appetite
    Start date: 2012-02-03
    End date: 2012-02-05

Megace
    Dosage: 3 df
    Administration route: Oral
    Start date: 2012-02-06
    End date: 2012-02-09

Other drugs received by patient: Calcium Gluconate; Pentasa; Vitamin B1 and B6; Bricanyl; Aluminum Hydroxide and Magnesium Trisilicate; Imodium; Decan; Magnesium Sulfate; Ascorbic Acid; Atrovent; Aspirin; Aldalix; Olimel; Cernevit-12; Phocytan; Nexium; Lovenox; Prednisolone; Fluticasone Propionate / Salmeterol; Singulair



Possible Megace side effects in 82 year old female

Reported by a physician from France on 2012-04-11

Patient: 82 year old female

Reactions: Thrombocytopenia

Adverse event resulted in: death, life threatening event

Drug(s) suspected as cause:
Citalopram Hydrobromide
    Administration route: Oral
    Indication: Depression
    Start date: 2012-01-19
    End date: 2012-02-10

Megace
    Dosage: 1df:1tab 3,4feb12-5feb12,3tabs 6,7feb12-9feb12
    Administration route: Oral
    Indication: Decreased Appetite
    Start date: 2012-02-03
    End date: 2012-02-09

Other drugs received by patient: Prednisolone; Imodium; Vitamin B1 TAB; Vitamin B6; Aldalix; Pentasa; Aspirin; Calcium Gluconate; Aluminum Hydroxide and Magnesium Trisilicate; Bricanyl; Cernevit-12; Fluticasone Propionate / Salmeterol; Phocytan; Magnesium Sulfate; Ascorbic Acid; Singulair; Atrovent; Nexium; Lovenox



Possible Megace side effects in female

Reported by a health professional (non-physician/pharmacist) from Denmark on 2012-04-04

Patient: female

Reactions: Overdose, Thrombocytopenia

Adverse event resulted in: death, life threatening event

Drug(s) suspected as cause:
Citalopram Hydrobromide
    Dosage: citalopram overdose: 60 mg daily
    Administration route: Oral
    Indication: Depression
    Start date: 2012-01-19
    End date: 2012-02-10

Megace
    Dosage: 1 df
    Administration route: Oral
    Indication: Decreased Appetite
    Start date: 2012-02-03
    End date: 2012-02-05

Megace
    Dosage: 3 df
    Administration route: Oral
    Start date: 2012-02-06
    End date: 2012-02-09

Other drugs received by patient: Aldalix; Fluticasone Propionate / Salmeterol; Aluminum Hydroxide and Magnesium Trisilicate; Decan; Aspirin; Cernevit-12; Magnesium Sulfate; Bricanyl; Pentasa; Olimel; Vitamin B1 and B6; Singulair; Calcium Gluconate; Ascorbic Acid; Atrovent; Imodium; Nexium; Lovenox; Phocytan; Prednisolone



Possible Megace side effects in 57 year old female

Reported by a consumer/non-health professional from United States on 2012-03-06

Patient: 57 year old female

Reactions: Disease Complication, Weight Decreased, Hepatitis C, Product Taste Abnormal

Adverse event resulted in: death

Drug(s) suspected as cause:
Megace



Possible Megace side effects in female

Reported by a consumer/non-health professional from United Kingdom on 2011-10-07

Patient: female

Reactions: Death, Vaginal Discharge

Adverse event resulted in: death

Drug(s) suspected as cause:
Megace

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017